|
|
Article: Par receives OK for generic Questran.(Par Pharmaceutical Inc.)(Brief Article)
- Article from:
- Pharma Marketletter
- Article date:
- September 5, 2005
CopyrightCOPYRIGHT 2005 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
USA-based Par Pharmaceutical, has received final Food and Drug Administration approval for its cholesterol drug cholestyramine, a generic version of Bristol-Myers Squibb's drug Questra.
The company says that the FDA has given approval for new applications for cholestyramine in the form of an oral suspension, which the firm intends to make available in ...
Related newspaper, magazine, and journal articles:
|
|
Article: IMS HEALTH Reports 31 Percent Earnings Per Share ...
Business Wire;
July 21, 1999 ;
700+ words
... ... Growth of 23 Percent Constant-Dollar IMS HEALTH (NYSE:RX) today announced that pro ... second quarter. Pro forma results reflect IMS HEALTH's recurring operations, excluding ... to be spun-off on July 26, 1999. IMS HEALTH is the world's leading provider of ...
|
|